Overview

* Treace Medical Q3 revenue grows 11% yr/yr, slightly beating analyst expectations

* The bunion correction implants maker reports Q3 net loss of $16.3 mln, adjusted EBITDA improves by 49%

* Treace revises full-year 2025 revenue guidance downward due to shifting surgeon preferences

Outlook

* Treace revises 2025 revenue guidance to $211 mln-$213 mln, down from $224 mln-$230 mln

* Company expects 2025 Adjusted EBITDA loss of $6.5 mln-$7.5 mln, previously breakeven

* Treace cites lower Lapiplasty sales due to surgeon preference shift and macroeconomic factors

Result Drivers

* MARKET PENETRATION - Revenue growth driven by greater market penetration and expanded portfolio of solutions, per CEO John T. Treace

* MINIMALLY INVASIVE SHIFT - Lapiplasty volumes impacted by shift in surgeon and patient preferences towards minimally invasive solutions, per CEO John T. Treace

* MACROECONOMIC HEADWINDS - Broader macroeconomic conditions and softer consumer sentiment leading to deferrals of elective bunion procedures, per CEO John T. Treace

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Slight $50.21 $49.73

Revenue Beat* mln mln (6

Analysts

)

Q3 EPS -$0.26

Q3 Gross 79.10%

Margin

Q3 Gross $39.71

Profit mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

* Wall Street's median 12-month price target for Treace Medical Concepts Inc ( TMCI ) is $7.00, about 10.7% above its November 5 closing price of $6.25

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)